Analysts rate BeiGene Ltd. (BGNE:NSD) with a Strong Buy rating and BGNE stock price target of $257

Based on the BeiGene Stock Forecast from 4 analysts, the average analyst BGNE stock price target is USD 257.80 over the next 12 months. BeiGene Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BGNE stock forecast is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, BeiGene stock price was USD 151.30BeiGene stock price has changed by +7.03% over the past week, -22.45% over the past month and -57.55% over the last year.

 

About BeiGene Ltd. (BGNE:NSD):

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA Tislelizumab REVLIMID, VIDAZA, XGEVA, BLINCYTO, KYPROLIS, SYLVANT, QARZIBA, and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

 

What we like:

High market capitalization

BGNE stock is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

BGNE stock has performed well, on a risk adjusted basis, compared to its sector peers (for a hold period of at least 12 months) and is in the top quartile.

Superior Revenue Growth

BGNE stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

 

What we don’t like:

High volatility

The total returns for Beigene stock are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

BGNE stock price is trading high compared to its peers median on a price to book value basis.

Negative cashflow

Beigene stock had negative total cash flow in the most recent four quarters.

Negative free cash flow

Beigene stock had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

BGNE stock has shown below median earnings growth in the previous 5 years compared to its sector.